Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Brondfield, Samuel Craig
Weinberg, Vivian K.
Koepfgen, Kathryn M.
Molina, Arturo
Ryan, Charles J.
Small, Eric Jay
Harzstark, Andrea Lynne
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15137
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study.
    Ryan, C. J.
    Harzstark, A. L.
    Lin, A. M.
    Fong, L.
    Grycz, K.
    Szmulewitz, R. Z.
    Weinberg, V. K.
    Molina, A.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [35] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.
    Maruzzo, Marco
    Basso, Umberto
    Diminutto, Alberto
    De Giorgi, Ugo
    Fratino, Lucia
    Lo Re, Giovanni
    D'Angelo, Alessandro
    Donini, Maddalena
    Verderame, Francesco
    Ratta, Raffaele
    Procopio, Giuseppe
    Campadelli, Enrico
    Massari, Francesco
    Gasparro, Donatello
    Macrini, Sveva
    Messina, Caterina
    Giordano, Monica
    Maines, Francesca
    Zagonel, Vittorina
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [37] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [38] A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Clayton, Ravinder
    Heng, Daniel Yick Chin
    Wu, Jackson S. Y.
    Zielinski, Rob
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien J.
    Al-Shamsi, Humaid Obaid
    Chen, Leo
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [39] The economics of abiraterone acetate for castration-resistant prostate cancer
    Dellis, Athanasios
    Papatsoris, Athanasios G.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) : 175 - 179
  • [40] Abiraterone Acetate, A Novel Adrenal Inhibitor in Metastatic Castration-Resistant Prostate Cancer
    Salem, Mohamed
    Garcia, Jorge A.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (02) : 92 - 96
12345